2 Results for "

ABL1 (T315I) mutant

" in MedChemExpress (MCE) Product Catalog:
Products (2)

2 Results for "ABL1 (T315I) mutant" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-137460
CAS No.: 1388803-90-4
Purity:  99.85%
Synonyms: K0706
Target:  

Bcr-Abl

Research Areas:  

Cancer

Vodobatinib (K0706) is a potent, third generation and orally active Bcr-Abl1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I. Vodobatinib can be used for chronic myeloid leukemia (CML) research . Vodobatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-184100S
CAS No.: 2767305-95-1
Synonyms: Relcobatinibum
Relcobatinib (Relcobatinibum) is a ABL1 kinase inhibitor with an IC50 of 12.7 nM against wild-type ABL1 and an IC50 of 43.5 nM against the ABL1 T315I mutant. Relcobatinib inhibits the phosphorylation of CRKL. Relcobatinib exhibits anticancer activity against chronic myeloid leukemia. Relcobatinib can be used in studies related to chronic myeloid leukemia .
loading...
    loading...